AlphAIAlphAI — Financial news for AI agents
tradingview.comJUL 311 min read$CGEN

CGEN Q2'26 Earnings: EPS estimate is (0.08) USD

Compugen Ltd. (CGEN) is scheduled to report Q2’26 results on Aug. 3 before market open, with release at 7:00 AM ET. The consensus estimates cited for Q2’26 are revenue of $1.28 million and EPS of -$0.08. The article references the company’s financials page for details.

Original reporting
tradingview.com
Published Jul 31, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CGEN Q2'26 Earnings: EPS estimate is (0.08) USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$CGENNeutralMed
01

Why it matters

Traders can use the stated consensus revenue ($1.28M) and EPS (-$0.08) to frame whether the upcoming print is likely to surprise and how to position into the event.

02

Market read

This is an earnings timing and consensus-expectations preview that can inform event-driven positioning and options implied-volatility expectations.

03

What to watch

The preview lacks guidance details, cash/burn commentary, and any pipeline or trial updates, which are often the real drivers of post-earnings repricing.

Relevance 6/10Novelty 5/10Timing: ahead of Aug 03 pre-market earnings release

Background

Compugen (CGEN) is set to announce Q2'26 results on Aug 03 at 7:00 AM ET (11:00 AM UTC).

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

CGEN is scheduled to report Q2'26 results Aug 03 before the open, with consensus revenue of $1.28M and EPS of -$0.08.

Expected impact

Likely elevated pre-earnings volatility around Aug 03, with direction dependent on whether reported results beat or miss the -$0.08 EPS and $1.28M revenue expectations.

Evidence & confidence

This is a forward-looking earnings preview with specific consensus numbers, which can drive positioning and implied volatility into the print, but it does not include any new post-release datapoint.

Market effects

Sector

Biotech/small-cap earnings calendar risk for oncology/biopharma names, but no sector-wide new information is disclosed.

Regional

Primarily US pre-market positioning around a single small-cap earnings event.

Global

Limited, as the article is company-specific and does not cite global regulatory or macro catalysts.

Counterpoint

What could challenge this read

Negative consensus EPS does not guarantee downside; if expectations are already low, a modest beat could still trigger a relief rally.

Key entities

  • public_company
    CGEN

    Compugen Ltd., scheduled to report Q2'26 results before market open on Aug 03.

Read at source← All news

Related articles

AUG 3
$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

prnewswire.com7 min
SEP 17
$TSLAHighAI 9/10

Tesla Posted Negative $1.1 Billion in Free Cash Flow Last Quarter as Elon Musk Ramps Up Spending on Robotaxis and Optimus. Here's Why the Company's $43.5 Billion Cash Cushion Still Matters.

Tesla reported a 26% revenue increase to $22.5B in Q2, with net income of $1.11B, but negative free cash flow of $1.1B due to $5.79B in capital expenditures. The company's $43.5B cash position provides a buffer for growth investments in robotaxis, Optimus robots, and semiconductors. Tesla's market share in U.S. EVs has risen despite industry contraction, but competition from Chinese rivals like BYD persists.

fool.com2 min
SEP 17
$BWINMed

Michael Dell Just Made a $7.7 Billion Bet on This Insurance Stock

Michael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.

yahoo.com2 min
SEP 17
$AMZNMedAI 8/10

Should You Buy Amazon Stock For The Demand AWS Cannot Yet Serve?

Amazon.com (AMZN) stock is down 13% from its 52-week high, despite AWS's 36.7% YOY revenue growth in Q2 2026. AWS's backlog of committed contracts reached $496 billion, with demand outpacing capacity. AWS's operating margin improved 520 basis points YOY, excluding energy contract gains. Management attributes growth to AI workloads and efficient capacity use.

yahoo.com3 min
SEP 17
$ASMLMedAI 8/10

Weakness Is an Opportunity for Long-Term ASML Stock Investors

ASML's High-NA technology is gaining traction among chipmakers like Samsung, Intel, and TSMC, crucial for its long-term outlook. Q2 earnings beat estimates with €7.59 EPS and €9.33B revenue. ASML raised full-year 2026 sales guidance to €43B-€45B. Analysts have a consensus 'Hold' rating, with a mean price target of $2,350.75, implying 56% upside.

yahoo.com3 min